Why we will need to learn new skills to control cancer

Internal Medicine Journal

Volumn 37, Issue 3, 2007, Pages 201-204

  Brown, M P ^a   Buckley, M F ^c   Rudzki, Z ^b   Olver, I N ^d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c New South Wales Government   (Australia)

^d CANCER COUNCIL AUSTRALIA   (Australia)

Author keywords

Cancer therapy; Cost effectiveness; Education; Medical oncology; Pathology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; RITUXIMAB; TEMOZOLOMIDE; TRASTUZUMAB;

BREAST CANCER; CANCER CONTROL; CANCER SURVIVAL; CANCER THERAPY; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; HUMAN; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; PATHOLOGIST; POSTGRADUATE EDUCATION; PRIORITY JOURNAL; REVIEW; TRAINING;

CLINICAL COMPETENCE; EDUCATION, MEDICAL, GRADUATE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 33846972953     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01285.x     Document Type: Review

References (18)

1. Jefford M, Savulescu J, Thomson J, Schofield P, Mileshkin L, Agalianos E et al. Medical paternalism and expensive unsubsidised drugs. BMJ 2005; 331: 1075-7.
2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
4. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11: 5878-85.
5. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005; 11: 3032-7.
6. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002; 297: 63-4.
7. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005; 65: 7525-9.
8. Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma. Cancer Cell 2005; 8: 439-41.
9. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-62.
10. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-98.
11. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003; 9: 2108-13.
12. Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 2004; 5 Suppl. 2: S51-5.
13. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
14. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-19.
15. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10 314-19.
16. Dalton WS, Friend SH. Cancer biomarkers - an invitation to the table. Science 2006; 312: 1165-8.
17. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
18. Varmus H. The new era in cancer research. Science 2006; 312: 1162-5.